Proposed subscription of new shares and new convertible bonds under specific mandate and (2) notice of extraordinary general meeting
Filed with HKEX · Stock code 2500 ·
6ix hasn’t read this filing yet.
Venus Medtech (Hangzhou), Inc. on 6ix
Earlier from Venus Medtech (Hangzhou)
- Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
- Court Sides with Cardiovalve in Edwards patent spat
- Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
- Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve
- Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement
Later from Venus Medtech (Hangzhou)
- Notice of extraordinary general meeting
- Proxy form for use at the egm
- 2026 Interim report
- Poll results of the extraordinary general meeting
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Venus Medtech (Hangzhou) into a list and get an email when it puts out news.
Follow Venus Medtech (Hangzhou)